Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 8/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.39 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.39 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.39 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8809376 | 0.86 | PARP1 (0.49) | KDM4EEGFRIRAK4GAKKDR | |
| SCHEMBL29728013 | 0.79 | MAP4K4 (0.54) | EGFR | |
| SCHEMBL5027281 | 0.79 | MAP4K4 (0.54) | EGFR | |
| SCHEMBL13043830 | 0.79 | EGFR (0.49) | EGFRIRAK4GAKRIPK2KDR | |
| SCHEMBL686704 | 0.79 | PDE4A (0.48) | EGFRIRAK4GAKABCG2TSHR | |
| SCHEMBL13078320 | 0.78 | EGFR (0.46) | EGFRIRAK4GAKRIPK2KDR | |
| SCHEMBL13043952 | 0.76 | EGFR (0.47) | EGFRIRAK4GAKRIPK2KDR | |
| SCHEMBL3737053 | 0.76 | HTT (0.49) | KDM4EEGFRABCG2HTTCCNC | |
| SCHEMBL4421437 | 0.75 | RIPK2 (0.53) | KDM4EEGFRIRAK4GAKRIPK2 | |
| SCHEMBL1192531 | 0.75 | PARP1 (0.47) | KDM4EEGFRABCG2HTTERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118900838-A | Heterocyclic compounds, compositions thereof and methods of treatment thereof | 百济神州有限公司 | 2024-11-05 | — | — | CN | disclosed |
| EP-3134091-A1 | IRAK INHIBITORS AND USES THEREOF | Nimbus Iris, Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. | 2015-11-19 | — | — | US | disclosed |
| WO-2015164374-A1 | IRAK INHIBITORS AND USES THEREOF | NIMBUS IRIS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| CN-101535301-B | Modulators of chemokine receptor activity, crystalline forms and methods | BRISTOL MYERS SQUIBB CO | 2014-06-18 | — | — | CN | disclosed |
| EP-1656345-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-1667966-B1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2012-02-29 | — | — | EP | disclosed |
| US-8049019-B2 | Substituted pyrrolidine-2-one compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-8049019-B2 | Substituted pyrrolidine-2-one compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-8049019-B2 | Substituted pyrrolidine-2-one compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-11-01 | — | — | US | disclosed |
| US-20050065147-A1 | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-24 | — | — | US | disclosed |
| WO-2005020899-A2 | SUBSTITUTED CYCLOALKYAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2005021498-A1 | LACTAMS OF ALKYLATED ACYCLIC DIAMINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021500-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021499-A1 | N-ALKYLATED DIAMINOPROPANE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050043392-A1 | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-02-24 | — | — | US | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| WO-2004071460-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | KDM4E 4716/4885EGFR 1758/4885IRAK4 254/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | KDM4E 4661/4885EGFR 2375/4885IRAK4 1077/4885 |
| US-20050065147-A1 | N-alkylated diaminopropane derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | KDM4E 4703/4885EGFR 2698/4885IRAK4 634/4885 |
| US-20150329498-A1 | IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 521/4885EGFR 4455/4885IRAK4 4/4885 |
| US-20050043392-A1 | Lactams of alkylated acyclic diamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | KDM4E 3783/4885EGFR 2105/4885IRAK4 349/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | KDM4E 4675/4885EGFR 1789/4885IRAK4 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.